Takeda Pharmaceutical Company Limited TAK
Annual
Quarterly
No annual revenue total was found in Takeda Pharmaceutical Company Limited's SEC filings.
Takeda Pharmaceutical Company Limited (TAK) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
—
Operating cash flow
—
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
1.59B
+0.5% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TAK (NYSE), TKPHF (OTC)
- Headquarters
- Tokyo, Japan
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1395064
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Oct 29, 2026 | Oct 29, 2026 |
| 6-K | Current report (foreign issuer) | Oct 29, 2026 | Oct 29, 2026 |
| 6-K | Current report (foreign issuer) | Sep 14, 2026 | Sep 14, 2026 |
| 6-K | Current report (foreign issuer) | Aug 31, 2026 | Aug 28, 2026 |
| 6-K | Current report (foreign issuer) | Aug 6, 2026 | Aug 5, 2026 |
| 6-K | Current report (foreign issuer) | Jul 30, 2026 | Jul 30, 2026 |
All 709 Takeda Pharmaceutical Company Limited SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.